Immunovant, Inc. / Fundamentals
Income statement
- Net revenue
€137.28K - Cost of goods sold
€160.45K - Gross profit
-€23.17K - SG&A expenses
€72.53M - R&D expenses
€331.74M - EBITDA
-€388.03M - D&A
€23.17K - EBIT
-€28.27M - Interest expenses
€0.00 - EBT
-€382.30M - Tax expenses
€1.48M - Net income
-€383.79M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€10.24M - Changes in working capital
-€6.67M - Operating cash flow
-€357.86M - Capex
€495.07K - Other investing cash flow
€0.00 - Net investing cash flow
-€495.07K - Total cash dividends paid
€0.00 - Issuance of common stock
€388.02M - Debt repayment
€0.00 - Other financing cash flow
€3.27M - Net financing cash flow
€391.87M - Foreign exchange effects
-€132.13K - Net change in cash
€33.38M - Cash at end of period
€513.87M - Free cash flow
-€357.37M
Balance sheet
- Cash and cash equivalents
€513.87M - Cash and short-term investments
€513.87M - Total receivables
€1.66M - Inventory
€0.00 - Other current assets
€43.69M - Total current assets
€559.21M - Property, plant & equipment
€632.35K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€7.67M - Total non-current assets
€8.30M - Total assets
€567.52M - Accounts payable
€6.73M - Short-term debt
€0.00 - Other current liabilities
€38.66M - Total current liabilities
€45.39M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€0.00 - Total liabilities
€45.39M - Common stock
€13.73K - Retained earnings
-€1.17B - Other equity
€1.49M - Total equity
€522.13M - Total liabilities and shareholders' equity
€567.52M
Company information
- Market capitalization
€2.35B - Employees
207 - Enterprise Value
€2.05B
Company ratios
- Gross margin
-
-16.9% Much better than peer group: -22,641.3% - EBITDA margin
-
-282,656.9% Much worse than peer group: -55,497.1% - EBIT margin
-
-20,589.4% Much better than peer group: -56,825.6% - EBT margin
-
-278,485.0% Much worse than peer group: -56,412.2% - Net margin
-
-279,564.4% Much worse than peer group: -56,092.5% - ROE
-
-73.5% Better than peer group: -80.9% - ROA
-
-67.6% Much worse than peer group: -43.3% - Asset turnover
-
0.0% Worse than peer group: 13.2% - FCF margin
-
-261,039.4% Much worse than peer group: -52,483.2% - FCF yield
-15.3% - Efficiency ratio
282,756.9% - Net sales per employee
-
€663.19 - Net income per employee
-
-€1.85M